ReviewClinical reviews in allergy & immunology2013
Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.
Review in Clinical reviews in allergy & immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- 2D Visualization of the Psoriasis Transcriptome Fails to Support the Existence of Dual-Secreting IL-17A/IL-22 Th17 T Cells.Frontiers in immunology · 2019Pooled it
- Meta-analysis of RNA sequencing datasets reveals an association between TRAJ23, psoriasis, and IL-17A.JCI insight · 2018Pooled it
- Question-Driven Selection of Psoriasis Animal Models: A Structured Narrative Review of 48 Model Records.Journal of inflammation research · 2026Review
- Toward Long-Acting Psoriasis Therapy with Phloretin-Loaded Microneedle Patches: Insights fromACS pharmacology & translational science · 2025Article
- Factors influencing the acceptability of different devices for subcutaneous drug delivery: a cross-sectional observational study from the patient's point of view.European journal of hospital pharmacy : science and practice · 2024Observational
- Antiproliferative and Anti-Inflammatory Effects of the Polyphenols Phloretin and Balsacone C in a Coculture of T Cells and Psoriatic Keratinocytes.International journal of molecular sciences · 2024Article
- The PEPSIN project: design and validation of a self-administered questionnaire for the assessment of equivalence between pens and prefilled syringes in patients on subcutaneous biological drugs.European journal of hospital pharmacy : science and practice · 2023Article
- Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema.Dermatology reports · 2022Article
- Myeloperoxidase Inhibition Ameliorates Plaque Psoriasis in Mice.Antioxidants (Basel, Switzerland) · 2021Article
- Cost-utility and budget impact analysis of adding-on apremilast to biologic therapy in the treatment of moderate to severe plaque psoriasis, an Iranian payer perspective.Research in pharmaceutical sciences · 2021Article
- Pyoderma gangrenosum.Nature reviews. Disease primers · 2020Review
- A Six-Year Analysis of Biological Therapy for Severe Psoriasis in a Lithuanian Reference Centre of Dermatovenereology.Medicina (Kaunas, Lithuania) · 2020Article
- A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience.Drug delivery · 2019Review
- Article
- Cutaneous and visceral leishmaniasis during anti-TNFα therapy.Wiener medizinische Wochenschrift (1946) · 2017Article
- Serial QuantiFERON-TB Gold testing in patients with psoriasis treated with ustekinumab.PloS one · 2017Article
- Interactions of the Immune System with Skin and Bone Tissue in Psoriatic Arthritis: A Comprehensive Review.Clinical reviews in allergy & immunology · 2016Review
- Providing Guidance for Patients With Moderate-to-Severe Psoriasis Who Are Candidates for Biologic Therapy: Role of the Nurse Practitioner and Physician Assistant.Journal of the Dermatology Nurses' Association · 2016Article
- Assessment and monitoring of biologic drug adverse events in patients with psoriasis.Psoriasis (Auckland, N.Z.) · 2016Review
- Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece.ClinicoEconomics and outcomes research : CEOR · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The treatment of psoriasis has undergone a revolution with the advent of biologic therapies including infliximab, etanercept, adalimumab, efalizumab, golimumab, certolizumab, alefacept, secukinumab, abatacept, and ustekinumab. These medications are designed to target specific components of the immune system and are a major technological advancement over traditional immunosuppressive medications. Herein, we present a comprehensive, unbiased comparison of these medications focusing on their differences. For example, TNF antagonists can differ in the way they are dissolved and administered, the effector molecules they can bind, serum peak and trough levels, the types of intracellular signals they can induce, the in vivo complexes that they can form, their protein structure, and their incidence and timing of rare adverse events, among other things. A critical review of the clinical studies that have tested the efficacy of these molecules is also presented including head-to-head comparison trials. The safety of biologics in terms of their long-term adverse events is discussed, as is their use in different types of psoriasis and in different patient populations. Finally, all anti-TNF agents have been associated with a variety of serious and "routine" opportunistic infections, particularly tuberculosis. For this reason, anti-tuberculosis testing both prior to the initiation of a biologic therapy and annually during treatment is pertinent. The uses and limitations of both the tuberculin skin test (TST) and QuantiFeron®-TB Gold (QFT) are discussed, as is the care of patients who present with latent tuberculosis infection prior to the initiation of biologic therapy. Recommendations for tuberculosis monitoring are provided.
Indexed as
Identifiers
22311162What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.